7 results
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Summary Table ... Insulin Lifestyle ... -4 inhibitors SGLT2 ... Improved outcomes in CKD ... #dm2
SGLT2 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits SGLT2 (sodium/glucose cotransporter 2) in the proximal tubule,
- Pharmacology Summary ... patients with T2D ... mL/minute/1.73 m2 ... #DM2 #diabetes ... #endocrinology
Sulfonylureas - Pharmacology Summary
Mechanisms of Action: Binds to the ATP-sensitive potassium channel in pancreatic beta cells,
- Pharmacology Summary ... cells, triggering insulin ... contraindicated in CKD ... #DM2 #diabetes ... #endocrinology
Estimating the Total Daily Dose (TDD) of Insulin: Weight-Based Dosing
TDD in units of insulin = N
(stage IV or V CKD ... including most type 1 diabetics ... including most 2 diabetics ... #pharmacology #endocrinology ... #diabetes #DM2
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Diabetes Mellitus ... Sulfonylurea, TZD ... receptor agonist, SGLT2i ... #Mellitus #DM2 ... comparison #table #endocrinology
Management of Diabetes Mellitus in Patients With CKD

1. Monitor for changes in BP, serum creatinine, &
patients with T2D ... ml/min per 1.73 m2 ... intermediate targets for glycemia ... #Diabetes #CKD # ... #KDIGO #eGFR #Insulin
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
- Pharmacology Summary ... glucose-dependent insulin ... patients with T2D ... #DM2 #diabetes ... #endocrinology